全球植入式去心房顫動（ICD）市場：市場規模、佔有率和趨勢分析（2025-2032 年）

全球植入式去心房顫動市場報告

2025年，全球植入式去心房顫動（ICD）市場規模超過31億美元。在預測期內，該市場預計將以4.0%的複合年成長率成長，達到約40.8億美元。

本報告對全球植入式去心房顫動（ICD）市場進行了分析，涵蓋單腔ICD、雙腔ICD、皮下ICD和血管外ICD。報告的結構和順序與附件中的範例文件相同，並針對全球ICD市場及其特定的競爭、技術和流程趨勢進行了客製化。

本報告詳細分析了銷售量、平均售價、治療量、市場規模和成長趨勢，包括截至2022年的歷史數據以及對未來市場發展的預測。該報告還涵蓋了市場促進因素和限制因素、近期併購、公司概況、產品系列和主要企業。因此，本報告對心臟節律管理領域最重要的治療類別之一提供了具有策略意義的觀點。

植入式心臟復律去顫器（ICD）市場已重回穩定成長軌道，這得益於結構性心臟疾病患者數量的不斷增加，以及一級和二級預防指南的持續完善。在關鍵地區，醫生仍然將ICD療法視為預防猝死的長期保護措施，這維持了穩定的銷售需求。這為市場奠定了堅實的臨床基礎，同時產品創新和競爭優勢也不斷發展。

總體而言，全球ICD市場在更廣泛的CRM產業中仍然是一個具有重要臨床意義和戰略意義的細分市場。該市場兼具穩固的現有需求基礎和充足的創新能力，足以在成熟市場和發展中市場維持長期價值成長。

市場概覽

全球植入式去心房顫動(ICD) 市場涵蓋用於檢測和治療危及生命的心室心律不整的植入式裝置。這些設備透過持續監測心率並在危險的心搏過速發生時進行治療，在預防猝死方面發揮核心作用。在某些情況下，根據平台的不同，它們還提供起搏支持，包括抗心搏過速起搏、心搏過緩起搏或相關的節律管理功能。

植入式心律轉復除顫器（ICD）仍然是心臟節律管理中最重要的治療方法之一，因為它適用於具有持續性和嚴重風險因素的患者。這些患者包括有心室心律不整病史、缺血性心肌病變、缺血性心肌病變以及其他增加猝死風險的結構性心臟疾病患者。隨著指南不斷強調ICD在初級和二級預防中的作用，市場正受益於穩定且具有臨床意義的需求基礎。

此類別涵蓋成熟和新興領域。傳統的經靜脈單腔和雙腔ICD仍佔據全球植入量的絕大部分，並且對許多患者群體至關重要。然而，皮下和血管外ICD等新型植入方式正日益影響市場。在某些情況下，這些新型植入方式可透過減輕導線帶來的負擔或無需植入標準經靜脈導線即可維持起搏功能，改變了醫師的選擇。

市場促進因素

新技術

全球ICD市場最強勁的驅動力之一是技術進步。目前的創新主要集中在設備小型化、延長電池壽命、改進感測演算法以及廣泛的無線連接，以支援持續的遠端追蹤。這些升級不僅提高了設備性能，還減少了更換設備的次數，有助於臨床醫生更有效地進行長期患者管理。

由於植入式心臟復律去顫器 (ICD) 的耗電量遠高於心臟節律器，電池創新尤其重要。提高電池效率和熱穩定性可以延長使用壽命，並減少發生器更換的頻率。這為醫生和醫療保健系統都創造了價值，因為更長的使用壽命可以改善長期經濟效益，並降低與更換相關的併發症風險。

設備設計的改進持續推動市場成長。機殼耐用性的提升、感染控制措施的改進以及導線性能的提升，都增強了人們對ICD治療的信心。在可靠性是購買和植入決策核心因素的市場中，這些特性至關重要。

擴大診斷範圍

另一個重要的促進因素是心律不整檢測範圍的擴大，這得益於心率更廣泛的監測。穿戴式感測器、長期心電圖監測和植入式監測器有助於識別以前可能未被發現的心室心律不整患者。隨著診斷範圍的擴大，越來越多的患者需要轉診至專科醫生，植入式心臟轉診途徑（ICD）治療也成為一種選擇。

這一點至關重要，因為它擴大了符合治療條件的患者群體，使其不再局限於那些已經出現明顯心律不整發作的患者。更早或更全面的檢測有助於建立更規範的轉診模式，並增強對植入式心臟復律去顫器（ICD）治療的整體需求。

無鉛替代系統

導線替代系統也正成為成長的主要驅動力。 EMBLEM S-ICD 無需使用經靜脈導線即可提供去心房顫動治療，其應用率持續保持高位，尤其受到希望減少某些患者導線相關併發症的醫生的青睞。該平台在臨床實踐中久經考驗的良好記錄和長期耐用性，持續推動其在關鍵市場的普及。

血管外植入系統正獲得進一步發展。 Aurora EV ICD 意義重大，因為它無需導線即可實現短時程起搏和抗心動過速起搏功能。這為那些因傳統皮下植入系統限制而難以應用的患者群體提供了顯著優勢。隨著這些系統得到更廣泛的認可和普及，它們正在幫助醫生重新定義 ICD 治療的概念。

市場限制

與設備和鉛相關的召回事件會導致市場佔有率劇烈波動。

ICD市場的主要阻礙因素是召回和安全事件的影響。與備受矚目的設備和導線相關的問題會迅速改變醫院的採購行為，並導致競爭對手之間的市場佔有率轉移。即使直接的臨床影響僅限於某些特定設備，這些事件也會影響醫生對更廣泛產品系列的信心。

近期的召回事件表明，此類產品對可靠性問題極為敏感。安全資訊揭露和召回措施可能引發更嚴格的審查、更早的更換以及採購政策的修訂，所有這些都可能只是短期的市場波動。這些事件也加劇了整個行業的監管審查，加重了製造商的負擔，並進一步凸顯了可靠性數據在未來採購決策中的重要性。

高昂的治療費用限制了其廣泛應用。

另一個主要的阻礙因素是ICD植入的總成本高。在已開發市場，經靜脈ICD手術費用昂貴，儘管許多醫療機構的保險報銷支持了治療的發展，但成本仍然是醫院在評估醫療設備選擇和病人就診時的重要考量。在開發中國家市場，這個問題更為嚴重，因為保險報銷往往有限或不穩定，可能導致患者自付費用更高。

這直接影響拉丁美洲、中東和非洲的普及率，這些地區的心血管疾病負擔日益加重，而高品質醫療器材療法的可近性仍然有限。在這些地區，臨床需求很高，但經濟障礙仍然阻礙醫療器材的普及。

已開發地區的市場成熟度

在許多已開發國家，ICD市場也受到市場成熟度的限制。這種治療方法已經非常成熟，其成長並非源自於全人群初始植入數量的急劇增加。相反，成長是由穩定的植入率、更換週期、技術升級以及在特定病患小組中的逐步推廣等因素共同驅動的。因此，該市場正經歷穩定成長，而非爆發式擴張。

市場覆蓋範圍和數據範圍

定量範圍

市場規模、市佔率、市場預測、市場成長率、銷售量、平均售價。

定性研究範圍

市場促進因素和阻礙因素、成長趨勢、近期併購、公司概況、產品系列和主要競爭對手。

目標期

基準年：2025 年，歷史資料截至 2022 年，並對報告期間進行預測。

包含的資料類型

銷售量、平均售價、治療次數、市場規模和成長趨勢。

本報告旨在透過將詳細的市場規模估算與影響 ICD 類別的技術和商業性因素的實際分析相結合，為策略規劃、產品定位和競爭基準分析提供支援。

目標市場及區隔

• 本報告涵蓋全球植入式去心房顫動（ICD）市場，並進一步細分為以下幾類：

單腔ICD市場

這部分包括主要用於心室感知和治療的標準經靜脈 ICD 系統，目標患者不需要更複雜的心室支持。

雙腔ICD市場

此部分包括具有雙腔感知和起搏功能的系統，以滿足更廣泛的心律不整管理需求。

皮下植入式心臟復律去顫器市場

此部分包括血管外無導線去心房顫動平台，為希望避免經靜脈導線植入的某些患者提供了替代方案。

血管外ICD市場

此部分包含一個新型系統，該系統在保持額外起搏功能的同時，避免了傳統的經靜脈導線植入。

每個細分市場均根據銷售量、平均售價和總市場價值進行分析，並包括報告期間的預測和截至 2022 年的歷史數據。

競爭分析

波士頓科學公司是ICD市場的全球領導者，擁有豐富的產品系列和最成熟的皮下ICD平台。其最顯著的競爭優勢源自於其在皮下ICD治療領域的領先地位。 EMBLEM MRI系統是目前唯一一款在全球範圍內廣泛應用且擁有深入臨床檢驗的皮下ICD，這使得波士頓科學公司在該領域最關鍵的高階細分市場之一中佔據了差異化且強大的地位。

在經靜脈植入式心律轉復除顫器（ICD）市場，波士頓科學公司的產品系列包括Dynagen、Dynagen Mini、Inogen和Inogen Mini。這些系統具有體積小巧、耐用性和先進的心律不整檢測功能。這些特性鞏固了波士頓科學公司在原發性和繼發性預防適應症領域的市場佔有率，並幫助其在全球主要市場保持強勁地位。

美敦力擁有第二大市場佔有率，並透過其廣泛且不斷更新的產品系列參與競爭，其中包括「Cobalt」、「Chrome」、「Evera MRI」和「Visia AF MRI」。該公司還憑藉「Aurora EV ICD」鞏固了其戰略地位，該產品為醫生提供了一種無需導線即可起搏的選擇，同時保留了包括抗心動過速起搏在內的起搏功能。這項特性尤其重要，因為它與現有的皮下植入式系統形成了明顯的差異化。美敦力的規模、全球分銷網路和強大的實證醫學證據進一步鞏固了其市場地位。

雅培在全球市場仍穩居第三大競爭對手的地位。其產品系列以Gallant為核心，該產品具有使用壽命長、診斷功能先進以及支援藍牙遠端監測等優勢。 Entrant則更著重於提升性價比，而Ellipse在以往廣受歡迎的地區依然佔有重要地位。儘管雅培已不再涉足皮下或血管外植入式心律轉復除顫器（ICD）領域，但憑藉其可靠性、緊湊的設計以及與廣泛的客戶關係管理（CRM）生態系統的整合，雅培在經靜脈ICD領域依然保持著競爭力。

技術和臨床趨勢

ICD市場最顯著的趨勢之一是導線替代系統的興起。皮下ICD已被公認為一種有效的治療選擇，而血管外ICD系統則透過保留額外的起搏功能進一步拓展了這個概念。

另一大趨勢是遠端監測技術的進步。最新的ICD擴大支援無線資料傳輸和基於雲端的追蹤功能，這改善了患者管理，並提高了治療的整體臨床價值。

電池壽命和感測精度不斷提高，減少了更換電池的負擔，增強了醫生對設備長期性能的信心。

最後，市場正朝著更具選擇性的優質化發展。以往所有ICD都被視為可互換的，而如今高階市場正日益根據導線策略、起搏功能、連接性和長期經濟價值進行明確分類。

地區

本報告提供了涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的全球研究成果。

本報告包含詳細的市場分析、市場區隔和預測數據，共 129 頁。

附錄：調查方法和縮寫詞彙表。

這份報告的意義

在整個預測期內，全球ICD市場最大的機會在哪裡？

皮下和血管外系統將如何重塑此類別的未來結構？

電池續航力、遠端監控和感測技術的進步將在競爭優勢方面發揮怎樣的作用？

召回、高昂的治療費用和進入障礙如何影響各地區的市場滲透率？

在經靜脈和導線置換型ICD系統市場中，哪家競爭對手佔據最有利的地位？

供應商、投資者和策略團隊應該如何評估最關鍵的高壓CRM市場之一的長期機會？

iData Research 的《全球植入式去心房顫動(ICD) 市場報告》透過詳盡的市場規模、價格分析、市場細分和競爭格局信息，解答了這些問題。您可以利用這份報告對標競爭對手，了解技術主導的成長，並幫助您在成熟但仍在不斷發展的全球 ICD 市場中製定策略。

目錄

圖表清單

調查方法

• 第一步：計劃啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 第四步：進行初步調查
• 第五步：調查與分析：建立基準估計值
• 第六步：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟九：客戶回饋與市場監測

全球關稅的影響

植入式去心房顫動市場

• 全球植入式去心房顫動市場概覽
• 競爭分析
• 流程分段
• 市場區隔
• 目標區域

介紹

手術次數

• 植入式去心房顫動（ICD）的整體流程
• 首次植入式去心房顫動（ICD）植入手術
• ICD更換手術

市場概覽

• 按細分市場
• 按地區

市場分析與預測

• ICD市場整體狀況
• 單腔ICD市場
• 雙腔ICD市場
• S-ICD市場
• 電動車植入式心臟復律去顫器市場

促進因素和抑制因素

競爭性市佔率分析

簡稱

Global Implantable Cardioverter Defibrillator Market Report

The global implantable cardioverter defibrillator market was valued at over $3.1 billion in 2025. Over the forecast period, the market is expected to grow at a CAGR of 4.0% to reach approximately $4.08 billion.

The full report suite on the global market for implantable cardioverter defibrillators, or ICDs, includes single-chamber ICDs, dual-chamber ICDs, subcutaneous ICDs and extra-vascular ICDs. This report follows the same structure and sequencing used in the attached example document, adapted to the global ICD market and its specific competitive, technological and procedural dynamics .

This report provides detailed analysis of unit sales, average selling prices, procedure numbers, market size and growth trends, with historical data to 2022 and forward-looking market forecasts across the forecast period. It also includes market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. The result is a focused strategic view of one of the most important therapy categories within cardiac rhythm management.

The ICD market has returned to a stable growth profile supported by consistent guideline reinforcement for both primary and secondary prevention, along with an expanding population of patients with structural heart disease. Across major regions, physicians continue to rely on ICD therapy for long-term protection against sudden cardiac death, which helps maintain steady unit demand. This gives the market a durable clinical foundation even as product innovation and competitive differentiation continue to evolve.

Overall, the global ICD market remains a clinically essential and strategically important segment of the broader CRM industry. It combines a large base of established demand with enough innovation to sustain long-term value growth across both mature and developing regions.

Market Overview

The global implantable cardioverter defibrillator market includes implantable devices used to detect and treat life-threatening ventricular arrhythmias. These devices play a central role in sudden cardiac death prevention by monitoring rhythm continuously and delivering therapy when dangerous tachyarrhythmias occur. In some cases, they also provide pacing support, including antitachycardia pacing, bradycardia pacing or related rhythm management functions depending on the platform.

ICDs remain one of the most important therapies in cardiac rhythm management because they serve patients with a persistent and serious risk profile. This includes patients with prior ventricular arrhythmias, ischemic cardiomyopathy, non-ischemic cardiomyopathy and other forms of structural heart disease that elevate the risk of sudden cardiac death. As guidelines continue reinforcing the role of ICDs in both primary and secondary prevention, the market benefits from a stable and clinically justified base of demand.

The category includes both mature and emerging segments. Traditional transvenous single-chamber and dual-chamber ICDs still account for a large portion of global implants and remain essential in many patient populations. However, the market is increasingly influenced by newer alternatives such as subcutaneous ICDs and extra-vascular ICDs, which are changing physician choice in selected cases by reducing lead-related burden or preserving pacing functionality without requiring standard transvenous lead placement.

Market Drivers

New Technologies

One of the strongest drivers in the global ICD market is technological advancement. Current innovation is centered on smaller device sizes, longer battery longevity, better sensing algorithms and broader wireless connectivity that supports continuous remote follow-up. These upgrades improve device performance while also reducing the replacement burden and helping clinicians manage patients more efficiently over time.

Battery innovation is especially important in ICDs because they consume substantially more power than pacemakers. Improvements in efficiency and thermal stability can extend service life and reduce the frequency of generator replacement procedures. This creates value for both physicians and health systems because longer longevity improves long-term economics and lowers exposure to replacement-related complications.

Device design improvements also continue to support growth. Better housing durability, infection mitigation strategies and stronger lead performance all reinforce confidence in ICD therapy. In a market where reliability is central to purchasing and implant decisions, these features matter greatly.

Growing Diagnostic Coverage

Another key driver is the expansion of arrhythmia detection through broader rhythm surveillance. Wearable sensors, extended ECG monitoring and implantable monitors are helping identify patients with ventricular arrhythmias who might previously have gone undetected. As diagnostic coverage expands, more patients are referred into specialist pathways where ICD therapy becomes an option.

This is important because it broadens the treatable population beyond patients with already obvious arrhythmic events. Earlier or more complete detection supports more consistent referral patterns and strengthens the overall demand base for ICD therapy.

Lead Alternative Systems

Lead alternative systems are also becoming a major source of growth. The EMBLEM S-ICD continues to benefit from strong adoption because it offers defibrillation therapy without transvenous leads, which appeals to physicians seeking to reduce lead-related complications in selected patients. The platform's established real-world performance and longevity profile continue to support its use in major markets.

Extra-vascular systems add a further layer of momentum. The Aurora EV ICD is significant because it delivers a lead-avoiding approach while still preserving short-duration pacing capability and antitachycardia pacing. This gives it an important advantage in patient groups where the limitations of current subcutaneous systems previously narrowed adoption. As these systems become more familiar and more broadly available, they are helping redefine how physicians think about ICD therapy.

Market Limiters

Device and Lead-Related Recalls Create Immediate Share Volatility

A major limiter in the ICD market is the effect of recalls and safety-related events. High-profile device and lead-related issues can quickly alter hospital purchasing behavior and shift market share between competitors. Even when the direct clinical impact is limited to a subset of devices, these events can affect physician confidence across broader product families.

Recent recall activity has shown how sensitive the category remains to reliability concerns. Safety communications and recall actions can trigger enhanced monitoring, early replacement activity and procurement reassessment, all of which add volatility to near-term market performance. These events also raise regulatory scrutiny across the category, increasing the burden on manufacturers and reinforcing the importance of reliability data in future purchasing decisions.

High Procedural Costs Limit Penetration

Another major limiter is the high total cost of ICD implantation. In developed markets, the cost of a transvenous ICD procedure is substantial, and while reimbursement may support therapy use in many settings, cost still influences how hospitals evaluate device choice and patient access. In developing markets, the problem is more severe because reimbursement coverage may be limited or inconsistent and out-of-pocket burden may be high.

This has a direct effect on penetration in Latin America, the Middle East and Africa, where cardiovascular disease burden is growing but access to premium device therapy remains more constrained. In those settings, the clinical need may be strong, but financial barriers continue to suppress adoption.

Market Maturity in Developed Regions

The ICD market is also limited by maturity in many developed countries. The therapy is already well established, and growth is not coming from a dramatic rise in first-time adoption across all populations. Instead, it comes from a combination of stable implant volume, replacement cycles, technology upgrades and incremental expansion in selected patient groups. This gives the market dependable growth, but not explosive expansion.

Market Coverage and Data Scope

Quantitative Coverage

Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Qualitative Coverage

Market drivers and limiters, growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Time Frame

Base year 2025, historical data to 2022 and forecasts through the report period.

Data Types Included

Unit sales, average selling prices, procedure numbers, market size and growth trends.

This report is designed to support strategic planning, product positioning and competitive benchmarking by combining detailed market sizing with practical analysis of the technological and commercial forces shaping the ICD category.

Markets Covered and Segmentation

• The report covers the Global Implantable Cardioverter Defibrillator Market, further segmented into:

Single-Chamber ICD Market

This segment includes standard transvenous ICD systems designed primarily for ventricular sensing and therapy in patients who do not require more complex chamber support.

Dual-Chamber ICD Market

This segment includes systems capable of dual-chamber sensing and pacing functionality, supporting a broader set of rhythm management needs.

Subcutaneous ICD Market

This segment includes lead-free defibrillation platforms placed outside the vasculature, offering an alternative for selected patients where transvenous lead avoidance is desirable.

Extra-Vascular ICD Market

This segment includes newer systems that avoid traditional transvenous lead placement while preserving additional pacing capabilities.

Each segment is analyzed by unit sales, average selling prices and total market value, with forecasts across the report period and historical data to 2022.

Competitive Analysis

Boston Scientific is the global leader in the ICD market, supported by a broad high-voltage portfolio and the most established subcutaneous ICD platform. Its most important competitive advantage comes from its leadership in subcutaneous ICD therapy. The EMBLEM MRI system remains the only widely adopted subcutaneous ICD with deep global clinical validation, giving Boston Scientific a differentiated and defensible position in one of the category's most important premium segments.

In transvenous ICDs, Boston Scientific's portfolio includes Dynagen, Dynagen Mini, Inogen and Inogen Mini. These systems offer compact form factors, strong longevity and advanced arrhythmia detection features. Together, they support Boston Scientific's share across both primary and secondary prevention indications and help maintain strong positioning in major global markets.

Medtronic holds the second-leading position and competes through a broad and consistently updated portfolio that includes Cobalt, Crome, Evera MRI and Visia AF MRI. The company also strengthened its strategic position with the Aurora EV ICD, which gives physicians a lead-avoiding option while preserving pacing capability, including antitachycardia pacing. That feature is especially important because it creates a meaningful distinction relative to already-established subcutaneous systems. Medtronic's scale, worldwide distribution and strong evidence base continue to reinforce its position.

Abbott remains the stable third-leading competitor in the global market. Its portfolio is led by Gallant, which offers long longevity, advanced diagnostics and Bluetooth-enabled remote monitoring. Entrant supports more value-oriented markets, while Ellipse remains relevant in regions where the platform has longstanding familiarity. Abbott does not currently compete in subcutaneous or extra-vascular ICDs, but it remains competitive in transvenous ICDs through reliability, compact design and integration with its broader CRM ecosystem.

Technology and Practice Trends

One of the most important trends in the ICD market is the rise of lead alternative systems. Subcutaneous ICDs have already established themselves as a meaningful therapy option, and extra-vascular systems are now expanding that concept by preserving additional pacing capability.

Another major trend is better remote monitoring. Modern ICDs increasingly support wireless data transfer and cloud-based follow-up, which improves patient management and strengthens the overall clinical value of therapy.

Battery longevity and sensing quality continue to improve, helping reduce replacement burden and increase physician confidence in long-term device performance.

Finally, the market is moving toward more selective premiumization. Rather than all ICDs being treated as interchangeable, premium segments are increasingly defined by lead strategy, pacing capability, connectivity and long-term economic value.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

129 pages of detailed market analysis, segmentation and forecast data.

Methodology Appendix and Acronym Glossary.

Why This Report

Where are the strongest opportunities in the global ICD market through the forecast period?

How are subcutaneous and extra-vascular systems changing the future structure of the category?

What role do battery life, remote monitoring and sensing improvements play in competitive differentiation?

How do recalls, high procedural costs and access barriers affect market penetration across regions?

Which competitors are best positioned in transvenous and lead alternative ICD systems?

How can suppliers, investors and strategy teams evaluate long-term opportunity in one of the most important high-voltage CRM markets?

The Global Implantable Cardioverter Defibrillator Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, segmentation and competitive intelligence. Use it to benchmark competitors, understand technology-driven growth and support strategy in a mature but still evolving global ICD market.

TABLE OF CONTENT

List Of Figures

List Of Charts

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Implantable Cardioverter Defibrillator Market

• 5.1.1 Global Implantable Cardioverter Defibrillator Market Overview
• 5.1.2 Competitive Analysis
• 5.1.3 Procedure Segmentation
• 5.1.4 Market Segmentation
• 5.1.5 Regions Included

Introduction

Procedure Numbers

• 5.1.6 Total Icd Placement Procedures
• 5.1.7 Initial Placement Icd Procedures
• 5.1.8 Replacement Icd Procedures

Market Overview

• 5.1.9 By Segment
• 5.1.1 By Region

Market Analysis And Forecast

• 5.1.2 Total Icd Market
• 5.1.1 Single-Chamber Icd Market
  • 5.1.1.1 Initial Placement Single-Chamber Icd Market
  • 5.1.1.2 Replacement Single-Chamber Icd Market
• 5.1.1 Dual-Chamber Icd Market
  • 5.1.1.1 Initial Placement Dual-Chamber Icd Market
  • 5.1.1.2 Replacement Dual-Chamber Icd Market
• 5.1.1 S-Icd Market
  • 5.1.1.1 Initial Placement S-Icd Market
  • 5.1.1.2 Replacement S-Icd Market
• 5.1.2 Ev-Icd Market

Drivers And Limiters

• 5.1.3 Market Drivers
• 5.1.4 Market Limiters

Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 5-1: Implantable Cardioverter Defibrillator Market, Global, 2025 & 2032
• Chart 5-2: Implantable Cardioverter Defibrillator Placement Procedures, Global, 2025
• Chart 5-3: ICD Placement Procedures by Segment, Global, 2022 - 2032
• Chart 5-4: ICD Market by Segment, Global, 2022 - 2032
• Chart 5-5: ICD Market by Region, Global, 2022 - 2032
• Chart 5-6: Leading Competitors, ICD Market, Global, 2025

LIST OF FIGURES

• Figure 5-1: Implantable Cardioverter Defibrillator Procedure Segmentation
• Figure 5-2: Implantable Cardioverter Defibrillator Market Segmentation
• Figure 5-3: Implantable Cardioverter Defibrillator Regions Covered, Global (1 of 2)
• Figure 5-4: Inferior Vena Cava Filter Regions Covered, Global (2 of 2)
• Figure 5-5: ICD Placement Procedures by Segment, Global, 2022 - 2032
• Figure 5-6: ICD Placement Procedures by Region, Global, 2022 - 2032
• Figure 5-7: ICD Placement Procedures by Country, North America, 2022 - 2032
• Figure 5-8: ICD Placement Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 5-9: ICD Placement Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 5-10: ICD Placement Procedures by Country, Western Europe, 2022 - 2032
• Figure 5-11: ICD Placement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 5-12: ICD Placement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 5-13: ICD Placement Procedures by Country, Middle East, 2022 - 2032
• Figure 5-14: ICD Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 5-15: ICD Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 5-16: ICD Placement Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 5-17: ICD Placement Procedures by Country, Africa, 2022 - 2032
• Figure 5-18: Initial Placement ICD Procedures by Region, Global, 2022 - 2032
• Figure 5-19: Initial Placement ICD Procedures by Country, North America, 2022 - 2032
• Figure 5-20: Initial Placement ICD Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 5-21: Initial Placement ICD Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 5-22: Initial Placement ICD Procedures by Country, Western Europe, 2022 - 2032
• Figure 5-23: Initial Placement ICD Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 5-24: Initial Placement ICD Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 5-25: Initial Placement ICD Procedures by Country, Middle East, 2022 - 2032
• Figure 5-26: Initial Placement ICD Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 5-27: Initial Placement ICD Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 5-28: Initial Placement ICD Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 5-29: Initial Placement ICD Procedures by Country, Africa, 2022 - 2032
• Figure 5-30: Replacement ICD Procedures by Region, Global, 2022 - 2032
• Figure 5-31: Replacement ICD Procedures by Country, North America, 2022 - 2032
• Figure 5-32: Replacement ICD Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 5-33: Replacement ICD Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 5-34: Replacement ICD Procedures by Country, Western Europe, 2022 - 2032
• Figure 5-35: Replacement ICD Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 5-36: Replacement ICD Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 5-37: Replacement ICD Procedures by Country, Middle East, 2022 - 2032
• Figure 5-38: Replacement ICD Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 5-39: Replacement ICD Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 5-40: Replacement ICD Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 5-41: Replacement ICD Procedures by Country, Africa, 2022 - 2032
• Figure 5-42: ICD Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 5-43: ICD Market by Region, Global, 2022 - 2032 (US$M)
• Figure 5-44: ICD Market, Global, 2022 - 2032
• Figure 5-45: Units Sold by Region, ICD Market, Global, 2022 - 2032
• Figure 5-46: Average Selling Price by Region, ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-47: Market Value by Region, ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-48: Single-Chamber ICD Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 5-49: Single-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-50: Units Sold by Region, Single-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-51: Average Selling Price by Region, Single-Chamber ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-52: Market Value by Region, Single-Chamber ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-53: Initial Placement Single-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-54: Units Sold by Region, Initial Placement Single-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-55: Average Selling Price by Region, Initial Placement Single-Chamber ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-56: Market Value by Region, Initial Placement Single-Chamber ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-57: Replacement Single-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-58: Units Sold by Region, Replacement Single-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-59: Average Selling Price by Region, Replacement Single-Chamber ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-60: Market Value by Region, Replacement Single-Chamber ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-61: Dual-Chamber ICD Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 5-62: Dual-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-63: Units Sold by Region, Dual-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-64: Average Selling Price by Region, Dual-Chamber ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-65: Market Value by Region, Dual-Chamber ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-66: Initial Placement Dual-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-67: Units Sold by Region, Initial Placement Dual-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-68: Average Selling Price by Region, Initial Placement Dual-Chamber ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-69: Market Value by Region, Initial Placement Dual-Chamber ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-70: Replacement Dual-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-71: Units Sold by Region, Replacement Dual-Chamber ICD Market, Global, 2022 - 2032
• Figure 5-72: Average Selling Price by Region, Replacement Dual-Chamber ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-73: Market Value by Region, Replacement Dual-Chamber ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-74: S-ICD Market by Segment, Global, 2022 - 2032 (US$M)
• Figure 5-75: S-ICD Market, Global, 2022 - 2032
• Figure 5-76: Units Sold by Region, S-ICD Market, Global, 2022 - 2032
• Figure 5-77: Average Selling Price by Region, S-ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-78: Market Value by Region, S-ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-79: Initial Placement S-ICD Market, Global, 2022 - 2032
• Figure 5-80: Units Sold by Region, Initial Placement S-ICD Market, Global, 2022 - 2032
• Figure 5-81: Average Selling Price by Region, Initial Placement S-ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-82: Market Value by Region, Initial Placement S-ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-83: Replacement S-ICD Market, Global, 2022 - 2032
• Figure 5-84: Units Sold by Region, Replacement S-ICD Market, Global, 2022 - 2032
• Figure 5-85: Average Selling Price by Region, Replacement S-ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-86: Market Value by Region, Replacement S-ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-87: EV-ICD Market, Global, 2022 - 2032
• Figure 5-88: Units Sold by Region, EV-ICD Market, Global, 2022 - 2032
• Figure 5-89: Average Selling Price by Region, EV-ICD Market, Global, 2022 - 2032 (US$)
• Figure 5-90: Market Value by Region, EV-ICD Market, Global, 2022 - 2032 (US$M)
• Figure 5-91: Leading Competitors, ICD Market, Global, 2025
• Figure 5-92: Leading Competitors by Region, ICD Market, Global, 2025
• Figure 5-93: Leading Competitors by Region, Single-Chamber ICD Market, Global, 2025
• Figure 5-94: Leading Competitors by Region, Dual-Chamber ICD Market, Global, 2025